Gemtuzumab Ozogamicin Maintenance

Benefits

Dosage & preparation

Risks & contraindications

Highlighted claims

• No dose-limiting toxicities occurred during GO maintenance dose escalation. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
• GO maintenance dose escalation tested 0.5, 1.0, and 2.0 mg/m2 with a 28-day dose-limiting toxicity period. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
• The recommended phase 2 GO maintenance dose was 2 mg/m2. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
• Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate approved for selected AML indications but limited after transplant by cytopenias. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
• The trial tested GO maintenance once every 28 days for up to eight cycles after remission and hematopoietic recovery assessment. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
• GO maintenance was associated with preserved neutrophil and platelet counts without prolonged high-grade cytopenias across dose cohorts. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial